Aging risk factors and Parkinson's disease: Contrasting roles of common dietary constituents

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1469-1472

  Hipkiss, Alan R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Carnosine; Dopamine; Energy metabolism; Fructose; Glucose; Glycolysis; Methylglyoxal; Salsolinol

Indexed keywords

ALPHA SYNUCLEIN; FRUCTOSE; GLUCOSE; CARBOHYDRATE DIET; CARNOSINE; METHYLGLYOXAL;

AGING; DIETARY INTAKE; ENERGY METABOLISM; ENZYME DEGRADATION; GLUCOSE METABOLISM; GLYCATION; GLYCOLYSIS; HUMAN; MITOPHAGY; NOTE; PARKINSON DISEASE; PHOTOSYNTHESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; CARBOHYDRATE DIET; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

AGING; ANIMALS; CARNOSINE; CLINICAL TRIALS AS TOPIC; DIETARY CARBOHYDRATES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; PARKINSON DISEASE; PYRUVALDEHYDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903363233     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.11.032     Document Type: Note

References (82)

1. Abe H. Role of histidine-related compounds as intracellular proton buffering constituents in vertebrate muscle. Biochemry (Mosc.) 2000, 65:757-765.
2. Adolphe J.L., Drew M.D., Huang Q., Silver T.I., Weber L.P. Postprandial impairment of flow-mediated dilation and elevated methylglyoxal after simple but not complex carbohydrate consumption. Nutrit. Res. 2012, 32:278-284.
3. Auburger G., Kurz A. The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety and Parkinson's disease. Aging 2011, 3:5-9.
4. Aviles-Olmos I., Limousine P., Lees A., Fontynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013, 136:374-384.
5. Baraniuk J.N., El-Amin S., Corey R., Rayhan R., Timbol C. Carnosine treatment for gulf war illness: a randomized controlled trial. Glob. J. Health Sci. 2013, 5:69-81.
6. Bauer K. Carnosine and homocarnosine, the forgotten and enigmatic peptides of the brain. Neurochem. Res. 2005, 30:1339-1345.
7. Beeri M.S., Moshier E., Schmeidler J., Godbold J., et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 2011, 132:583-587.
8. Bellia F., Calabrese V., Guarino F., Cavallaro M., et al. Carnosinase levels in aging brain: redox state induction and cellular stress response. Antioxid. Redox Sign. 2009, 11:2759-2775.
9. Bellia F., Vecchio G., Cuzzocrea S., Calabrese V., Rizzarelli E. Neuroprotective features of carnosine in oxidative disease. Mol. Aspects Med. 2011, 32:258-266.
10. Bitel C.L., Kasinathan C., Kaswala R.H., Klein W.L., Frederikse P.H. Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in an animal model. J.Alzheimers Dis. 2012, 32:291-305.
11. Boldyrev A.A., Fedorova T., Stepanova M., Dobrotvorskaya I., et al. Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot study. Rejuvenation Res. 2008, 11:821-827.
12. Boldyrev A.A., Fedorova T., Stvolinsky S., Borras C., et al. Chemical intervention in senescence-accelerated mice metabolism for modelling neurodegenerative disease: an overview. Int. Cong. Ser. 2004, 1260:109-115.
13. Boldyrev A.A., Stvolinsky S.L., Fedorova T.N., Suslina Z.A. Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. Rejuvenation Res. 2010, 13:156-158.
14. Brownson C., Hipkiss A.R. Carnosine reacts with a glycated protein. Free Rad. Biol. Med. 2000, 28:1564-1570.
15. Campello L., Esteve-Rudd J., Bru-Martinez R., Herrero M.T., Fernandez-Villalba E., Cuenca N., Martin-Nieto J. Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian MPTP-treated monkeys. PLoS One 2013, 8:e74439.
16. Cartwright S., Bill R.M., Hipkiss A.R. Carnosine affects the growth of Saccharomycer cerevisiae in a metabolism-dependent manner. PLoS One 2012, 7:e45006.
17. Cereda E., Barichella M., Cassani E., Caccialanza R., Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 2012, 78:1507-1511.
18. Cheng B., Yang X., An L., Gao B., et al. Ketogenic diet protects dopaminergic neurones against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease. Brain Res. 2009, 1286:25-31.
19. Chengappa K.N., Turkin S.R., DeSanti S., Bowie C.R., Brar J.S., Schlicht P.j., et al. Apreliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr. Res. 2012, 142:145-152.
20. Chez M.G., Buchanon C.P., Aimonovitch M.C. Double-blind, placebo-controlled studyn of L-carnosine supplementation in children with autistic spectrum disorders. J.Child Neurol. 2002, 17:833-837.
21. Chua L.S. A review on plant-based rutin extraction methods and its pharmacological activities. J. Ethnopharmacol. 2013, 150:805-817.
22. Cook C., Stetler C., Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009423.
23. Corona C., Frazzini V., Silvestri E., Lattanzio R., et al. Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PLoS One 2011, 6:e17971.
24. Dhar I., Dhar A., Wu L., Desa K.M. Increased methylglyoxal formation with upregulation of renin angiotensin system in fructose-fed Sprague- Dawley rats. PLoS One 2013, 8:e74212.
25. Deng Y., Zhang Y., Li Y., Xiao S., et al. Occurrence and distribution of a salsolinol-like compound, 1-acetyl-6.7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in Parkinsonian brains. J.Neural Transm. 2012, 119:435-441.
26. Desai K.M., Chang T., Wang H., Banigesh A., Dhar A., Liu J., Untereiner A., Wu L. Oxidative stress and aging: is methylglyoxal the hidden enemy?. Can. J. Physiol. Pharmacol. 2010, 88:273-284.
27. Dranka B.P., Zielonka J., Kanthasamy A.G., Kalyanaramen B. Alterations in bioenergetic function induced by disease mimetic compounds: lack of correlation with superoxide generation. J.Neurochem. 2012, 122:941-951.
28. Dunn L., Allen G.f.g, Mamais A., Ling H., Li A., Duberly K.E., Hargreaves I.P., et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson disease. Neurobiol. Aging 2014, 35:1111-1115.
29. Dunnet M., Harris R.C. High-performance liquid chromatographic determination of imidazole dipeptides, histidine, 1-methylhistidine and 3-methylhistdine in equine and camel muscle and individual fibres. J.Chromatogr. B Biomed. Sci. Appl. 1997, 688:47-55.
30. Ferrer I., Martinez A., Bianco R., Dalto E., Carmona M. Neuropathology of sporadic Parkinson's disease before the appearance of parkinsonianism: preclinical Parkinson's disease. J.Neural. Transm. 2011, 118:821-839.
31. Fontana M., Pinnen F., Lucente G., Pecci L. Prevention of peroxynitrite-dependent damage by carnosine and related sulphonamido pseudodipeptides. Cell Mol. Life Sci. 2002, 59:546-551.
32. Gao C., Hölscher C., Liu Y., Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 2011, 23:1-11.
33. Gomez A., Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body disease. J.Neurosci. Res. 2009, 87:1002-1013.
34. Hipkiss A.R. Could carnosine or related structures suppress Alzheimer's disease?. J.Alzheimers Dis. 2007, 11:229-240.
35. Hipkiss A.R. Carnosine and its possible roles in nutrition and health. Adv. Food Nutrit. Res. 2009, 57:87-154.
36. Hipkiss A.R., Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem. Biophys. Res. Commun. 1998, 248:28-32.
37. Hipkiss A.R., Worthington V.C., Himsworth D.T., Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim. Biophys. Acta 1998, 1380:46-64.
38. Im J.Y., Lee K.W., Woo J.M., Junn E., Mouradian M.M. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum. Mol. Gen. 2012, 21:3013-3024.
39. Janssen B., Hohenadel D., Brinkkoeter P., Peters V., et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005, 54:2320-2327.
40. Jia H., Qi X., Fang S., Jin Y., Han X., Wang Y., Wng A., Zhou H. Carnosine inhpbits high glucose-induced mesangial proliferation through mediating cell cycle progression. Regul. Pept. 2009, 154:69-75.
41. Kang J.H. Salsolinol, a catechol neurotoxin, induces modification of ferritin: protection by histidine dipeptide. Environ. Toxicol. Pharmacol. 2010, 29:246-251.
42. Kohen R., Yamamoto Y., Cundy K.C., Ames B.N. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc. Natl. Acad. Sci. U.S.A 1988, 85:3175-3179.
43. Krautwald M., Münch G. Advanced glycation end products as biomarkers and gerontotoxins: a basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Exp. Gerontol. 2010, 45:744-751.
44. Kroner Z. The relation ship between A.D. and diabetes: type-3 diabetes?. Altern. Med. Rev. 2009, 4:373-379.
45. Kurz A., Rabbani N., Walter M., Thornalley P., et al. α-Synuclein deficiency leads to increased glyoxalase 1 expression and glycation stress. Cell Mol. Life Sci. 2011, 68:721-733.
46. Lee J.Y., Song J., Kwon K., Jang S. Human DJ-1 and its homologs are novel glyoxalases. Hum. Mol. Genet. 2012, 21:3215-3225.
47. Lee Y., Hsu C., Lin K., Yin M. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur. J. Pharmacol. 2005, 512:145-150.
48. Li X.-H., Xie J.-Z., Jiang X., Ly B.-L., et al. Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromol. Med. 2012, 14:338-348.
49. Licker V., Côte M., Lobrinus J.A., Rodrigo N., et al. Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease. J.Proteomics 2012, 75:4656-4667.
50. Maher P.A., Schubert D.R. Metabolic links between diabetes and Alzheimer's disease. Expert Rev. Neurother. 2009, 9:617-630.
51. McFarland G.A., Holliday R. Retardation of senescence of cultured human diploid fibroblasts by carnosine. Exp. Cell Res. 1994, 212:167-175.
52. de la Monte S.M., Wands J.R. Alzheimer's disease is type-3 diabetes - evidence reviewed. J.Diabetes Sci. Tech. 2008, 2:1101-1113.
53. Munch G., Westcott B., Menini T., Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 2012, 42:1221-1226.
54. Murakami K., Miyake Y., Sasaki S., Tanaka K., et al. Dietary glycemic index is inversely associated with the risk of Parkinson's disease: a case-control study in Japan. Nutrition 2010, 26:515-521.
55. Okubo H., Miyake Y., Sasaki S., Murakami K., et al. Dietary patterns and risk of Parkinson's disease: a case-control study in Japan. Eur. J. Neurol. 2012, 19:681-688.
56. Pfister F., Riedl E., Wang Q., vorn Hagen F., Deinzer M., Harmsen M.C., et al. Oral carnosine supplemantation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol. Biochem. 2011, 28:125-136.
57. Phillipson O.T. Management of the aging risk for Parkinsons disease. Neurobiol. Aging 2014, 35:847-857.
58. Pun P.B., Murphy M.P. Pathological significance of mitochondrial glycation. Int. J. Cell Biol. 2012, Article ID 843505.
59. Quinn P.J., Boldyrev A.A., Formazuyk V.E. Carnosine: its properties, functions and potential therapeutic applications. Mol. Aspects Med. 1992, 13:379-444.
60. Rabbini N., Thornalley P.J. Methylglyoxal, glyoxalase-1 and the dicarbonyl proteome. Amino Acids 2012, 42:1133-1142.
61. Ramkissoon J.S., Mahomoodally M.F., Ahmed N., Subratty A.H. Antioxidant and anti-glycating activities correlate with phenolic composition of tropical medicinal herbs. Asian Pac. J. Trop. Med. 2013, 6:561-569.
62. Renner C., Asperger A., Seyffarth A., Meixensberger J., et al. Carnosine inhibits ATP production in cells from malignant glioma. Neurol. Res. 2010, 32:101-105.
63. Shao L., Li Q.H., Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem. Biophys. Res. Commun. 2004, 324:931-936.
64. Sims-Robinson C., Kim B., Rosko A., Feldman E.L. How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 2010, 6:551-559.
65. Son D.O., Satsu H., Kiso Y., Totsuka M., Shimizu M. Inhibitory effect of carnosine on interleukin-8 production in intestinal epithelial cells through translational regulation. Cytokine 2008, 42:265-276.
66. Stafstrom C.E., Rho J.M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol. 2012, 3:59.
67. Szent-Gyorgyi A., McLaughlin J.A. Interaction of glyoxal and methylgyoxal and biogenic amines. Proc. Natl. Acad. Sci. U.S.A 1975, 72:1610-1611.
68. Tallon M.J., Harris R.C., Maffulli N., Tarnopolsky M.A. Carnosine, taurine and enzyme activities of human skeletal muscle fibres from elderly subjects with osteoarthritis and young moderately active subjects. Biogerontology 2007, 8:129-137.
69. Tatone C., Heizenrieder T., Di Emidio G., Treffon P., et al. Evidence that carbonyl stress by methylglyoxal exposure induces DNA damage and spindle aberrations, affects mitochondrial integrity in mammalian oocytes and contributes to oocyte ageing. Hum. Reprod. 2011, 26:1843-1859.
70. Tsai S.J., Kuo W.W., Liu W.H., Yin M.C. Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice. J.Agric. Food Chem. 2010, (in press) PMID:20925384.
71. Uchiki T., Weikel K.A., Jiao W., Shang F., et al. Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell 2012, 11:1-13.
72. Untereiner A.A., Dhar A., Liu J., Wu L. Increased renal methylglyoxal formation with down-regulation of PGC-1α-FBPase pathway in cystathione-γ-lyase knockout mice. PLoS One 2011, 6:e29592.
73. Verma, M., Steer, E.K., Chu, C.T. ERKed by LRRK2. a cell biological perspective on hereditary and sporadic Parkinson's disease. Biochim. Biophys. Acta. (in press). http://dx.doi.org/10.1016/j.bbadis.2013.11.005.
74. Vincent A., Briggs L., Chatwin G.F.J., Emery E., et al. Parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum. Mol. Gen. 2012, 21:1760-1769.
75. Wahlqvist M.L., Lee M.S., Hsu C.C., Chuang S.Y., et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 2012, 18:753-758.
76. Wan O.W., Chung K.K. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS One 2012, 7:e38545.
77. Xue M., Rabbani N., Momiji H., Imbasi P., et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem. J. 2012, 443:213-222.
78. Yaffe K., Falvey C., Hamilton N., Schwartz A.V., et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia/diabetes and risk of cognitive decline. Arch Neurol. 2012, 18:1-6.
79. Yang X., Cheng B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J.Mol. Neurosci. 2010, 42:145-153.
80. Yuneva M.O., Bulygina E.R., Gallant S.C., Kramarenko G.G., et al. Effect of carnosine on age-induced changes in senescence-accelerated mice. J.Anti Aging Med. 1999, 2:337-342.
81. Yuneva A.O., Kramarenko G.G., Vetreshchak T.V., Gallant S.C., Boldyrev A.A. Effect of carnosine on Drosophila melanogaster lifespan. Bull. Exp. Biol. Med. 2002, 133:559-561.
82. Zhang C., Lin M., Wu R., Wang X., et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16259-16264.